Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Hepatol
    August 2021
  1. DO CARMO RF, de Souza CDF
    Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.
    >> Share

    July 2021
  2. BORGIA SM, Shafran SD
    Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
    J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.
    >> Share

  3. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
    Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
    J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
    >> Share

    June 2021
  4. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
    Anti-epileptic drugs and hepatitis C therapy: real world experience.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.
    >> Share

  5. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    >> Share

    May 2021
  6. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    >> Share

  7. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
    >> Share

  8. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
    Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
    >> Share

  9. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
    Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
    J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
    >> Share

  10. CRESPO J, Diaz-Gonzalez A, Cabezas J
    HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
    J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.
    >> Share

    April 2021
  11. DIETZ J, Sarrazin C
    Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.
    >> Share

  12. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
    Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
    >> Share

    March 2021
  13. CRESPO J, Lazarus JV, Iruzubieta P, Garcia F, et al
    Let's leverage SARS-CoV2 vaccination to screen for hepatitis C screening in Spain, in Europe, around the world.
    J Hepatol. 2021 Mar 20. pii: S0168-8278(21)00181.
    >> Share

    February 2021
  14. MARTIN MT, Patel S, Kulik L, Chan C, et al
    Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    J Hepatol. 2021 Feb 27. pii: S0168-8278(21)00158.
    >> Share

  15. CAPRARU C, Feld JJ
    Remaining challenges in HCV elimination.
    J Hepatol. 2021 Feb 12. pii: S0168-8278(20)33845.
    >> Share

    January 2021
  16. GIACOMELLI A, Pagani G, Conti F, Bassoli C, et al
    Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00009.
    >> Share

  17. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    >> Share

  18. LIU CH, Kao JH
    Reply to: "Sofosbuvir and the risk of kidney dysfunction".
    J Hepatol. 2021;74:257-258.
    >> Share

    December 2020
  19. BUTI M, Dominguez-Hernandez R, Casado MA
    Impact of the COVID 19 Pandemic on HCV Elimination in Spain.
    J Hepatol. 2020 Dec 20. pii: S0168-8278(20)33891.
    >> Share

  20. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    >> Share

  21. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    >> Share

  22. ZEUZEM S
    Introducing the HCV miniseries.
    J Hepatol. 2020;73:1306.
    >> Share

  23. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    >> Share

  24. NEGRO F
    Residual risk of liver disease after hepatitis C virus eradication.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33827.
    >> Share

    November 2020
  25. KUSHNER T, Reau N
    Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33814.
    >> Share

  26. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    >> Share


  27. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33741.
    >> Share

  28. DAI CY, Chuang WL, Yu ML
    EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33693.
    >> Share

  29. WEINFURTNER K, Reddy KR
    Hepatitis C Viremic Organs in Solid Organ Transplantation.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33767.
    >> Share

  30. AQEL B, Wijarnpreecha K, Pungpapong S, Taner CB, et al
    Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33754.
    >> Share

  31. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    >> Share

    October 2020
  32. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    >> Share

  33. CRESPO J, Diaz-Gonzalez A, Iruzubieta P, Llerena S, et al
    SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33679.
    >> Share

    September 2020
  34. THIMME R
    T cell immunity to hepatitis C virus: lessons for a prophylactic HCV vaccine.
    J Hepatol. 2020 Sep 28. pii: S0168-8278(20)33665.
    >> Share

  35. VALERIO H, Alavi M, Law M, Tillakeratne S, et al
    High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)33618.
    >> Share

  36. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    TEMPORARY REMOVAL: Reduced incidence of hepatitis C in nine villages in rural Egypt: Progress towards national elimination goals.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)33619.
    >> Share

  37. VIRZI A, Roca Suarez AA, Lupberger J
    Interferon revisited: Peering behind the lines of antiviral defense.
    J Hepatol. 2020;73:496-498.
    >> Share

    August 2020
  38. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    >> Share

  39. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    >> Share


  40. EASL recommendations on treatment of hepatitis C - Final update of the series.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30548.
    >> Share

  41. CHALOUNI M, Pol S, Sogni P, Fontaine H, et al
    Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    J Hepatol. 2020 Aug 13. pii: S0168-8278(20)30535.
    >> Share

  42. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    >> Share

  43. BLACH S, Kondili LA, Aghemo A, Cai Z, et al
    Impact of COVID-19 on global hepatitis C elimination efforts.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30523.
    >> Share

  44. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    >> Share

  45. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    >> Share

    July 2020
  46. PAWLOTSKY JM
    About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus.
    J Hepatol. 2020 Jul 27. pii: S0168-8278(20)30402.
    >> Share

  47. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    >> Share

  48. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    >> Share

  49. LENS S, Miquel M, Mateos-Munoz B, Garcia-Samaniego J, et al
    SARS-CoV2 in patients on antiviral HBV and HCV therapy in Spain.
    J Hepatol. 2020 Jul 13. pii: S0168-8278(20)30460.
    >> Share

  50. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    >> Share

    June 2020
  51. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    >> Share

  52. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    >> Share

  53. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    >> Share

  54. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    >> Share

  55. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    >> Share

    May 2020
  56. NGUYEN D, Smith D, Vaughan-Jackson A, Magri A, et al
    Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30348.
    >> Share

  57. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".
    J Hepatol. 2020;72:1036-1037.
    >> Share

  58. INNES HA, McDonald SA, Barclay ST, Irving WL, et al
    The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut.
    J Hepatol. 2020;72:1034-1035.
    >> Share

    April 2020
  59. ROY A, De A, Singh V
    DAAs and HBV/HCV coinfection: Glimmer of light and a few shades of grey.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30169.
    >> Share

  60. YEH ML, Yu ML
    Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30203.
    >> Share

  61. KINAST V, Plociennikowska A, Anggakusuma, Bracht T, et al
    C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30209.
    >> Share

    March 2020
  62. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    >> Share

  63. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    >> Share

  64. BOON D, Bruce V, Patel EU, Quinn J, et al
    Antibody avidity-based approach to estimate population-level incidence of hepatitis C.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30190.
    >> Share

  65. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(19)30645.
    >> Share

  66. BUTT AA, Yan P, Shaikh OS, Lo Re V 3rd, et al
    Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30120.
    >> Share

    February 2020
  67. HAN JW, Sung PS, Hong SH, Lee H, et al
    IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30107.
    >> Share

  68. YEH ML, Huang CF, Huang CI, Holmes JA, et al
    Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    J Hepatol. 2020 Feb 13. pii: S0168-8278(20)30074.
    >> Share

  69. LAMPERTICO P, Carrion JA, Curry M, Turnes J, et al
    Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30072.
    >> Share

  70. FELD JJ
    HCV elimination: It will take a village and then some.
    J Hepatol. 2020 Feb 11. pii: S0168-8278(20)30002.
    >> Share

  71. SOLOMON SS, McFall AM, Lucas GM, Mehta SH, et al
    Response to: 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' by Seung KJ et al.
    J Hepatol. 2020 Feb 10. pii: S0168-8278(20)30061.
    >> Share

  72. SKINNER NE, Bailey JR
    Broadly neutralizing antibodies against hepatitis C virus: location, location, location.
    J Hepatol. 2020 Feb 1. pii: S0168-8278(20)30020.
    >> Share

  73. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    >> Share

  74. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    >> Share

    January 2020
  75. MARCELLIN F, Di Beo V, Aumaitre H, Mora M, et al
    Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).
    J Hepatol. 2020 Jan 7. pii: S0168-8278(19)30646.
    >> Share

    December 2019
  76. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".
    J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30702.
    >> Share

  77. CHILDS K, Cannon M, Davis C, Thompson EC, et al
    Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action".
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30697.
    >> Share

  78. HOORNENBORG E, Coyer L, Boyd A, Alfons Achterbergh RC, et al
    High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.
    J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30719.
    >> Share

  79. GUPTA N, Kateera F, Desalegn H, Ocama P, et al
    Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30644.
    >> Share

  80. AVERHOFF F, Shadaker S, Gamkrelidze A, Kuchuloria T, et al
    Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.
    J Hepatol. 2019 Dec 4. pii: S0168-8278(19)30710.
    >> Share

    November 2019
  81. LIU CH, Lee MH, Lin JW, Liu CJ, et al
    Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.
    J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30701.
    >> Share

  82. BRASHER NA, Eltahla AA, Underwood A, Boo I, et al
    B cell immunodominance in primary hepatitis C virus infection.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30698.
    >> Share

  83. HAJARIZADEH B, Cunningham EB, Valerio H, Martinello M, et al
    Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699.
    >> Share

  84. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
    >> Share

  85. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
    Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
    J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
    >> Share

    October 2019
  86. ALAVI M, Law MG, Dore GJ
    Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis".
    J Hepatol. 2019 Oct 24. pii: S0168-8278(19)30419.
    >> Share

  87. DORE GJ, Feld JJ, Thompson A, Martinello M, et al
    Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612.
    >> Share

  88. PAWLOTSKY JM
    DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?
    J Hepatol. 2019 Oct 21. pii: S0168-8278(19)30587.
    >> Share

  89. LAPOINTE-SHAW L, Austin PC, Chung H, Sander B, et al
    Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis.
    J Hepatol. 2019 Oct 21. pii: S0168-8278(19)30387.
    >> Share

  90. PONS M, Rodriguez-Tajes S, Esteban JI, Marino Z, et al
    Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals.
    J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606.
    >> Share

  91. MACIAS J
    Reply to: "Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes".
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30530.
    >> Share

  92. SUHAS SOLOMON S, Quinn TC, Solomon S, McFall AM, et al
    Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    J Hepatol. 2019 Oct 8. pii: S0168-8278(19)30588.
    >> Share

  93. VRANCKEN B, Cuypers L, Perez AB, Chueca N, et al
    Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30476.
    >> Share

    September 2019
  94. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    >> Share

    August 2019
  95. CHILDS K, Davis C, Cannon M, Montague S, et al
    Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C.
    J Hepatol. 2019 Aug 7. pii: S0168-8278(19)30468.
    >> Share

  96. DEGASPERI E, Spinetti A, Lombardi A, Landonio S, et al
    Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461.
    >> Share

  97. ROSSI C, Jeong D, Wong S, McKee G, et al
    Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30462.
    >> Share

    July 2019
  98. DHIMAN RK, Grover GS, Premkumar M, Taneja S, et al
    Decentralized Care with Generic Direct-Acting Antivirals in the Management of Chronic Hepatitis C in a Public Health Care Setting.
    J Hepatol. 2019 Jul 17. pii: S0168-8278(19)30414.
    >> Share

  99. AREGAY A, Sekyere SO, Deterding K, Port K, et al
    Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30397.
    >> Share

  100. COMARMOND C, Lorin V, Marques C, Maciejewski-Duval A, et al
    TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30401.
    >> Share

  101. AVERHOFF F, Lazarus JV, Sergeenko D, Colombo M, et al
    Excellence in Viral Hepatitis Elimination - Lessons from Georgia.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30398.
    >> Share

    June 2019
  102. LLANERAS J, Riveiro-Barciela M, Lens S, Diago M, et al
    Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345.
    >> Share

  103. BORGIA SM, Dearden J, Yoshida EM, Shafran SD, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30343.
    >> Share

  104. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".
    J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30280.
    >> Share

  105. YAU T, Hsu C, Kim TY, Choo SP, et al
    Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.
    J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300.
    >> Share

  106. WILSON E, Covert E, Hoffmann J, Comstock E, et al
    A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY).
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307.
    >> Share

    May 2019
  107. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    >> Share

  108. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30278.
    >> Share

  109. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    >> Share

  110. ALAVI M, Law MG, Valerio H, Grebely J, et al
    Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    J Hepatol. 2019 May 9. pii: S0168-8278(19)30275.
    >> Share

    April 2019
  111. HONG J, Kushner T, Dieterich D, Garry D, et al
    Reducing mother-to-child transmission of HCV: Is it attainable with a multidisciplinary approach?
    J Hepatol. 2019 Apr 24. pii: S0168-8278(19)30079.
    >> Share

  112. WRENSCH F, Keck ZY, Foung SKH, Baumert TF, et al
    Learning from a clinical cohort for HCV vaccine development.
    J Hepatol. 2019 Apr 13. pii: S0168-8278(19)30224.
    >> Share

  113. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    >> Share

  114. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    >> Share

  115. UMUTESI G, Shumbusho F, Kateera F, Serumondo J, et al
    Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.
    J Hepatol. 2019 Apr 1. pii: S0168-8278(19)30179.
    >> Share

    March 2019
  116. DENG L, Jiang W, Wang X, Merz A, et al
    Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.
    J Hepatol. 2019 Mar 14. pii: S0168-8278(19)30147.
    >> Share

  117. FONTAINE H, Alric L, Labreuche J, Legendre B, et al
    Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    J Hepatol. 2019 Mar 9. pii: S0168-8278(19)30020.
    >> Share

  118. WYLES D, Weiland O, Yao B, Weilert F, et al
    Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    J Hepatol. 2019 Mar 8. pii: S0168-8278(19)30078.
    >> Share

    February 2019
  119. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30128.
    >> Share

  120. MORGAN FREIMAN J, Wang J, Easterbrook PJ, Robert Horsburgh C, et al
    Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30125.
    >> Share

  121. BANDA DH, Perin PM, Brown RJP, Todt D, et al
    A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30110.
    >> Share

  122. KEMMING J, Reeves E, Nitschke K, Widmeier V, et al
    ERAP1 allotypes impact the epitope repertoire of virus-specific CD8(+) T cell responses in acute hepatitis C virus infection.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30111.
    >> Share

    January 2019
  123. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    >> Share

  124. PAPALUCA T, McDonald L, Craigie A, Gibson A, et al
    Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30024.
    >> Share

    December 2018
  125. DENOLLY S, Granier C, Fontaine N, Pozzetto B, et al
    A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32619.
    >> Share

  126. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    >> Share

    November 2018
  127. MODIN L, Arshad A, Wilkes B, Benselin J, et al
    Epidemiology and natural history of hepatitis C virus infection among children and young people.
    J Hepatol. 2018 Nov 26. pii: S0168-8278(18)32545.
    >> Share

  128. VAN SEYEN M, Smolders EJ, van Wijngaarden P, Drenth JPH, et al
    Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32492.
    >> Share

  129. D'AMBROSIO R, Pasulo L, Puoti M, Vinci M, et al
    Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32543.
    >> Share

  130. COSTA R, Todt D, Zapatero-Belinchon F, Schenk C, et al
    SEC14L2, a lipid-binding protein, regulate HCV replication in culture with inter- and intra- genotype variations.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32544.
    >> Share

  131. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    >> Share

  132. KHERA T, Behrendt P, Bankwitz D, Brown RJP, et al
    Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32527.
    >> Share


  133. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    >> Share

  134. PHAM LV, Jensen SB, Fahnoe U, Pedersen MS, et al
    HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    J Hepatol. 2018 Nov 2. pii: S0168-8278(18)32515.
    >> Share

    October 2018
  135. JENNY I, Gregory JD, Beth C, Philip C, et al
    Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32494.
    >> Share

  136. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    >> Share

  137. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    >> Share

  138. NISHIBATAKE KINOSHITA M, Minami T, Tateishi R, Wake T, et al
    Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32454.
    >> Share

  139. NEWSUM AM, Molenkamp R, van der Meer JT, Rebers SP, et al
    Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.
    J Hepatol. 2018;69:968-970.
    >> Share

  140. BERENGUER M, de la Rosa Rodriguez G, Dominguez-Gil B
    Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain.
    J Hepatol. 2018;69:966-968.
    >> Share

  141. DEUFFIC-BURBAN S, Huneau A, Verleene A, Brouard C, et al
    Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    J Hepatol. 2018;69:785-792.
    >> Share

    September 2018
  142. BELPERIO PS, Shahoumian TA, Loomis TP, Mole LA, et al
    Real-world Effectiveness of Daclatasvir plus Sofosbuvir and Velpatasvir/Sofosbuvir in Hepatitis C Genotype 2 and 3.
    J Hepatol. 2018 Sep 25. pii: S0168-8278(18)32392.
    >> Share

    August 2018
  143. ROSSI C, Butt Z, Wong S, Buxton J, et al
    Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32288.
    >> Share

  144. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    >> Share

  145. TERRAULT NA, Pageaux GP
    A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32276.
    >> Share

  146. SARRAZIN C, Cooper CL, Manns MP, Reddy KR, et al
    No Impact of Resistance Associated Substitutions on the Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir for 12 Weeks in HCV DAA-experienced Patients.
    J Hepatol. 2018 Aug 8. pii: S0168-8278(18)32279.
    >> Share

  147. HERZER K, Gerken G, Kroy D, Tacke F, et al
    Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32179.
    >> Share

    July 2018
  148. VERMEHREN J, Park JS, Jacobson I, Zeuzem S, et al
    Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32181.
    >> Share

  149. GRAUPERA I, Lammert F
    Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32125.
    >> Share

    June 2018
  150. MARSHALL AD, Pawlotsky JM, Lazarus JV, Aghemo A, et al
    The removal of DAA restrictions in Europe - one step closer to eliminating HCV as a major public health threat.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)32169.
    >> Share

  151. BELLI LS, Perricone G, Adam R, Cortesi PA, et al
    Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    J Hepatol. 2018 Jun 22. pii: S0168-8278(18)32163.
    >> Share

  152. ROCA SUAREZ AA, Baumert TF, Lupberger J
    Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.
    J Hepatol. 2018 Jun 21. pii: S0168-8278(18)32118.
    >> Share

  153. FORNS X, Sarrazin C
    Treatment of chronic hepatitis C.
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32019.
    >> Share

  154. AGARWAL K, Castells L, Mullhaupt B, Rosenberg WMC, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32124.
    >> Share

    May 2018
  155. OJHA RP, Steyerberg EW
    Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
    J Hepatol. 2018 May 26. pii: S0168-8278(18)31980.
    >> Share

  156. CHEVALIEZ S, Pawlotsky JM
    New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.
    J Hepatol. 2018 May 22. pii: S0168-8278(18)32063.
    >> Share

  157. BUGGISCH P, Zeuzem S
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32051.
    >> Share

    April 2018
  158. BLOOM S, Kemp W, Nicoll A, Roberts SK, et al
    Liver Stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver related events in hepatitis C.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32023.
    >> Share

  159. GROEPPER C, Rufinatscha K, Schroder N, Stindt S, et al
    HCV modifies EGF signalling and upregulates production of CXCR2 ligands: role in inflammation and antiviral immune response.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32013.
    >> Share


  160. EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Apr 9. pii: S0168-8278(18)31968.
    >> Share

  161. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty MI, et al
    A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30174.
    >> Share

  162. NAKAO Y, Hashimoto S, Abiru S, Komori A, et al
    Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
    J Hepatol. 2018;68:854-855.
    >> Share

    March 2018
  163. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    >> Share

  164. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    >> Share

  165. PETTA S, Adinolfi LE, Fracanzani AL, Rini F, et al
    Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132.
    >> Share

  166. TOYODA H, Kumada T, Tada T, Mizuno K, et al
    Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR.
    J Hepatol. 2018;68:606-607.
    >> Share

  167. CAMMA C, Leandro G
    Direct antiviral agents and risk of HCC: Waiting for Godot.
    J Hepatol. 2018;68:614-616.
    >> Share

    February 2018
  168. CRESPO G, Trota N, Londono MC, Mauro E, et al
    The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in wait-list composition.
    J Hepatol. 2018 Feb 23. pii: S0168-8278(18)30129.
    >> Share

    January 2018
  169. LEMOINE M, Cooke GS
    The Egyptian hepatitis C programme: a model of HCV treatment intervention?
    J Hepatol. 2018 Jan 30. pii: S0168-8278(18)30068.
    >> Share

  170. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    >> Share

  171. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens.
    J Hepatol. 2018 Jan 12. pii: S0168-8278(18)30014.
    >> Share

  172. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    >> Share

    December 2017
  173. SCHWARZINGER M, Rehm J, Mallet V
    "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 30. pii: S0168-8278(17)32539.
    >> Share

  174. ALAVI M, Law MG, Dore GJ
    Reply to: "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 29. pii: S0168-8278(17)32538.
    >> Share

  175. AMPUERO J, Jimeno C, Quiles R, Rosales JM, et al
    Impact of comorbidities on patients outcomes after interferon-free therapy-induced viral eradication in hepatitis.
    J Hepatol. 2017 Dec 27. pii: S0168-8278(17)32535.
    >> Share

  176. SCOTT N, Olafsson S, Gottfreethsson M, Tyrfingsson T, et al
    Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
    J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32528.
    >> Share

  177. SODERHOLM J, Millbourn C, Busch K, Kovamees J, et al
    Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32485.
    >> Share

  178. HELLARD M, Scott N, Sacks Davis R, Pedrana A, et al
    Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32486.
    >> Share

  179. ASSELAH T, Hassanein T, Waked I, Mansouri A, et al
    Eliminating Hepatitis C within Low Income Countries - the need to cure Genotypes 4, 5, 6.
    J Hepatol. 2017 Dec 8. pii: S0168-8278(17)32482.
    >> Share

  180. ELSHARKAWY A, Raziky ME, Akel WE, Saeed KE, et al
    Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32478.
    >> Share

  181. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    >> Share

  182. HEZODE C, Reau N, Svarovskaia ES, Doehle BP, et al
    Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32476.
    >> Share

    November 2017
  183. HUPA KL, Deterding K, Port K, Kimmann M, et al
    In Reply to: EASL RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2016 "Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?"
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32443.
    >> Share

  184. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    >> Share

  185. BUGGISCH P, Vermehren J, Mauss S, Gunther R, et al
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431.
    >> Share

  186. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    >> Share

    October 2017
  187. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    >> Share

  188. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    >> Share

  189. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    >> Share

  190. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    >> Share

  191. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    >> Share

  192. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    >> Share

  193. HALFON P, Scholtes C, Izopet J, Larrat S, et al
    Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    J Hepatol. 2017 Oct 4. pii: S0168-8278(17)32333.
    >> Share

    September 2017
  194. DI MAIO VC, Cento V, Aragri M, Paolucci S, et al
    Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?
    J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32288.
    >> Share

  195. LIU X, Shen JJ, Jung Kim S, Lee YJ, et al
    Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32290.
    >> Share

  196. ESMAT G, Elbaz T, El Raziky M, Gomaa A, et al
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis c genotype-4.
    J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32286.
    >> Share

  197. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    >> Share

  198. CARRIERI MP, Protopopescu C, Marcellin F, Rosellini S, et al
    Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32211.
    >> Share

  199. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    >> Share

  200. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    >> Share

  201. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.
    J Hepatol. 2017 Sep 4. pii: S0168-8278(17)32259.
    >> Share

    August 2017
  202. CALVARUSO V, Craxi A
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back.
    J Hepatol. 2017 Aug 29. pii: S0168-8278(17)32256.
    >> Share

  203. KRAMER L, Laurain A, Sultanik P, Tremeaux P, et al
    "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32251.
    >> Share

  204. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    >> Share

  205. PASCASIO JM, Vinaixa C, Ferrer MT, Colmenero J, et al
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    J Hepatol. 2017 Aug 22. pii: S0168-8278(17)32215.
    >> Share

  206. MELE D, Mantovani S, Oliviero B, Grossi G, et al
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32203.
    >> Share

  207. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    >> Share

  208. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    >> Share

  209. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    >> Share

  210. ZEUZEM S, Dvory-Sobol H, Brainard DM
    No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32191.
    >> Share

  211. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32195.
    >> Share

    July 2017
  212. LAZARUS JV, Wiktor S, Colombo M, Thursz M, et al
    Micro-elimination - A path to global elimination of hepatitis C.
    J Hepatol. 2017 Jul 28. pii: S0168-8278(17)32141.
    >> Share

  213. SUDA T, Shimakami T, Shirasaki T, Yamashita T, et al
    Reactivation of Hepatitis B Virus from an isolated Anti-HBc positive patient after eradication of Hepatitis C Virus with Direct-acting Antiviral Agents.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32158.
    >> Share

  214. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    >> Share

  215. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    >> Share

    June 2017

  216. Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C.
    J Hepatol. 2017 Jun 29. pii: S0168-8278(17)32129.
    >> Share

  217. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    >> Share

  218. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    >> Share

  219. SUSSER S, Dietz J, Schlevogt B, Zuckerman E, et al
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    J Hepatol. 2017 Jun 12. pii: S0168-8278(17)32069.
    >> Share

    May 2017
  220. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    >> Share

  221. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    >> Share

  222. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    >> Share

    April 2017
  223. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    >> Share

  224. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    >> Share

  225. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    >> Share

  226. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    >> Share

  227. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    >> Share

  228. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    >> Share

  229. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    >> Share

  230. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    >> Share

  231. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    >> Share

  232. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    >> Share

  233. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    >> Share

  234. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    >> Share

  235. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    >> Share

    March 2017
  236. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    >> Share

  237. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    >> Share

  238. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    >> Share

  239. BELLI LS, Duvoux C, Berg T, Strazzabosco M, et al
    ELITA consensus statements on use of DAAs in liver transplant candidates and recipients.
    J Hepatol. 2017 Mar 18. pii: S0168-8278(17)30140.
    >> Share

  240. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    >> Share

  241. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    >> Share

    February 2017
  242. PIROTH L, Wittkop L, Lacombe K, Rosenthal E, et al
    Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30107.
    >> Share

  243. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    >> Share

  244. OLIVIERO B, Mantovani S, Varchetta S, Mele D, et al
    Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30069.
    >> Share

  245. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    >> Share

  246. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    >> Share

  247. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059.
    >> Share

  248. CALLEJA JL, Crespo J, Rincon D, Ruiz-Antoran B, et al
    Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30063.
    >> Share

  249. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    >> Share

  250. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    >> Share

  251. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    >> Share

    January 2017
  252. FARQUHAR MJ, Humphreys IS, Rudge SA, Wilson GK, et al
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30013.
    >> Share

  253. ZEUZEM S, Mizokami M, Pianko S, Mangia A, et al
    NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011.
    >> Share

  254. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    >> Share

    December 2016
  255. LANGHANS B, Dieter Nischalke H, Kramer B, Hausen A, et al
    Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30752.
    >> Share

  256. FERNANDEZ I, Munoz-Gomez R, Pascasio JM, Baliellas C, et al
    Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis c.
    J Hepatol. 2016 Dec 27. pii: S0168-8278(16)30753.
    >> Share

  257. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    >> Share

  258. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    >> Share

  259. WYLES D, Dvory-Sobol H, Svarovskaia Doehle ES, Martin R, et al
    Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir.
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699.
    >> Share

    November 2016
  260. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    >> Share

  261. TOYODA H, Kumada T, Tada T, Shimada N, et al
    Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30686.
    >> Share

  262. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    >> Share

  263. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    >> Share

  264. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    >> Share

  265. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    >> Share

    October 2016
  266. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    >> Share

  267. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    >> Share

  268. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    >> Share

  269. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    >> Share

  270. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    >> Share

  271. CACOUB P, Desbois AC, Isnard-Bagnis C, Rocatello D, et al
    Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    J Hepatol. 2016;65.
    >> Share

  272. MAASOUMY B, Vermehren J
    Diagnostics in hepatitis C: The end of response-guided therapy?
    J Hepatol. 2016;65.
    >> Share

  273. EASTERBROOK PJ
    Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    J Hepatol. 2016;65.
    >> Share

  274. MIDGARD H, Weir A, Palmateer N, Lo Re V 3rd, et al
    HCV epidemiology in high-risk groups and the risk of reinfection.
    J Hepatol. 2016;65.
    >> Share

  275. HEIM MH, Bochud PY, George J
    Host - hepatitis C viral interactions: The role of genetics.
    J Hepatol. 2016;65.
    >> Share

  276. BUKH J
    The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    J Hepatol. 2016;65.
    >> Share

  277. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    >> Share

  278. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    >> Share

  279. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    >> Share

    September 2016
  280. INGILIZ P, Martin TC, Rodger A, Stellbrink HJ, et al
    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30505.
    >> Share


  281. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    >> Share

  282. POL S, Bourliere M, Lucier S, Hezode C, et al
    Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    J Hepatol. 2016 Sep 10. pii: S0168-8278(16)30486.
    >> Share

    July 2016
  283. NAULT JC, Colombo M
    Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
    J Hepatol. 2016 Jul 11. pii: S0168-8278(16)30327.
    >> Share

    May 2016
  284. BELLI LS, Berenguer M, Cortesi PA, Strazzabosco M, et al
    DELISTING OF LIVER TRANSPLANT CANDIDATES WITH CHRNIC HEPATITIC C AFTER VIRAL ERADICATION: A EUROPEAN STUDY.
    J Hepatol. 2016 May 17. pii: S0168-8278(16)30196.
    >> Share

  285. PADEGIMAS A, Forde KA, Goldberg LR, Birati EY, et al
    Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    J Hepatol. 2016;64:1196-8.
    >> Share

    January 2016
  286. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    >> Share

    September 2015
  287. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    >> Share

    August 2015
  288. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    >> Share

  289. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016